Free Trial

Eli Lilly and Company (LLY) Stock Price, News & Analysis

$951.97
+2.00 (+0.21%)
(As of 08/21/2024 ET)
Today's Range
$939.17
$956.50
50-Day Range
$772.14
$951.97
52-Week Range
$516.57
$967.00
Volume
2.50 million shs
Average Volume
3.10 million shs
Market Capitalization
$904.76 billion
P/E Ratio
140.20
Dividend Yield
0.55%
Price Target
$956.88

Eli Lilly and Company MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
0.5% Upside
$956.88 Price Target
Short Interest
Healthy
0.64% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
0.66mentions of Eli Lilly and Company in the last 14 days
Based on 56 Articles This Week
Insider Trading
Selling Shares
$1.07 B Sold Last Quarter
Proj. Earnings Growth
40.97%
From $13.79 to $19.44 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.71 out of 5 stars

Medical Sector

43rd out of 924 stocks

Drug Manufacturers - General Industry

1st out of 1 stocks

LLY stock logo

About Eli Lilly and Company Stock (NYSE:LLY)

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

LLY Stock Price History

LLY Stock News Headlines

In this photo The logo of Merck and Co, Inc.Merck is an American multinational pharmaceutical company
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why (LLY)
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,
Financial markets news icon
MarketBeat Week in Review – 8/5 - 8/9 (LLY)
Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings
Secure this "AI Fuel" Stock Before the Billionaires Buy It All
According to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.
Amgen injection syringe
Amgen's MariTide Weight Loss Potential: Stock Outlook (LLY)
Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials.
A dose of injectable Ozempic from Danish company Novo Nordisk
Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings (LLY)
Novo Nordisk fell over 8% after its earnings release but recovered nearly all of those losses the next day. It needs to increase supplies of semaglutide.
Obesity drugs
It's Too Soon to Buy the Dip in Weight Loss Drugmakers
Obesity drugs are a hot market and one still accelerating as new treatments are approved and usage widens. The bad news is that much of the growth is priced in.
Financial markets news icon
How major US stock indexes fared Thursday, 8/8/2024
U.S. stocks rallied to their best day since 2022 following an encouraging update on the job market
A sign for Eli Lilly & Co
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarter
li Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker
Secure this "AI Fuel" Stock Before the Billionaires Buy It All
According to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.
Eli Lilly and Company (NYSE:LLY) Shares Down 0.2%
Why Eli Lilly Topped the Market on Tuesday
Eli Lilly: Tirzepatide's Winning Streak Continues
Why Eli Lilly Stock Jumped to a Record High on Tuesday
See More Headlines
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/06/2024
Ex-Dividend for 6/10 Dividend
5/15/2024
Dividend Payable
6/10/2024
Ex-Dividend for 9/10 Dividend
8/15/2024
Today
8/22/2024
Dividend Payable
9/10/2024
Next Earnings (Estimated)
11/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
Pharmaceuticals
CUSIP
53245710
Employees
39,000
Year Founded
1876

Price Target and Rating

Average Stock Price Target
$956.88
High Stock Price Target
$1,125.00
Low Stock Price Target
$710.00
Potential Upside/Downside
+0.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
18 Analysts

Profitability

Net Income
$5.24 billion
Pretax Margin
21.04%

Debt

Sales & Book Value

Annual Sales
$38.92 billion
Cash Flow
$8.72 per share
Book Value
$11.44 per share

Miscellaneous

Free Float
949,169,000
Market Cap
$904.76 billion
Optionable
Optionable
Beta
0.41

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

  • Eli Lilly and Company has a strong dividend history, currently offering a $1.30 dividend per share, representing a 0.59% yield. This consistent dividend payout can provide investors with a steady income stream.
  • Insider activity shows major shareholders selling shares at high prices, indicating confidence in the company's future growth prospects. This can be seen as a positive signal for potential investors.
  • Institutional investors have been increasing their stakes in Eli Lilly and Company, suggesting a favorable outlook on the company's performance and potential for growth.
  • The company's market capitalization of $885.38 billion reflects its strong position in the market, indicating stability and potential for long-term growth.
  • Eli Lilly and Company's P/E ratio of 137.16 and a PEG ratio of 1.81 suggest that the stock may be undervalued compared to its growth potential, making it an attractive investment opportunity.

Cons

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

  • The company's payout ratio of 76.58% indicates that a significant portion of its earnings is being distributed as dividends, potentially limiting reinvestment for future growth initiatives.
  • Recent insider selling activity, including by major shareholders and executives, could raise concerns about the company's internal outlook or potential challenges ahead.
  • Eli Lilly and Company's beta of 0.41 suggests that the stock may be less volatile compared to the market, which could limit potential returns for investors seeking higher-risk opportunities.
  • The debt-to-equity ratio of 1.90 indicates that the company relies heavily on debt financing, which may pose risks in case of economic downturns or rising interest rates.
  • While the stock has shown stability, the current stock price may be considered high based on the company's financial metrics, potentially limiting immediate upside potential for investors.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, August 15, 2024. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

LLY Stock Analysis - Frequently Asked Questions

How have LLY shares performed this year?

Eli Lilly and Company's stock was trading at $582.92 at the start of the year. Since then, LLY shares have increased by 63.3% and is now trading at $951.97.
View the best growth stocks for 2024 here
.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) posted its earnings results on Monday, May, 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.05. The firm's revenue was up 26.0% compared to the same quarter last year.
Read the conference call transcript
.

What is David A. Ricks' approval rating as Eli Lilly and Company's CEO?

399 employees have rated Eli Lilly and Company Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.

Does Eli Lilly and Company have any subsidiaries?

The following companies are subsidiaries of Eli Lilly and Company: Protomer Technologies, Prevail Therapeutics Inc., Disarm Therapeutics, Disarm Therapeutics, Dermira, Loxo Oncology, CoLucid Pharmaceuticals, and more.

Who are Eli Lilly and Company's major shareholders?

Eli Lilly and Company's top institutional investors include Primecap Management Co. CA (2.06%), Legal & General Group Plc (0.75%), Bank of New York Mellon Corp (0.69%) and Dimensional Fund Advisors LP (0.38%). Insiders that own company stock include Lilly Endowment Inc, Jackson P Tai, Anne E White, Patrik Jonsson, Johna Norton, Alonzo Weems, Donald A Zakrowski, Acquisition Corp Kearny, Marschall S Runge and Ilya Yuffa.
View institutional ownership trends
.

How do I buy shares of Eli Lilly and Company?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Eli Lilly and Company own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eli Lilly and Company investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY) and Walt Disney (DIS).

This page (NYSE:LLY) was last updated on 8/22/2024 by MarketBeat.com Staff

From Our Partners